Circulating FGF23 Levels in Heart Failure

Have Imazu et al discovered a new clinical biomarker for predicting renal dysfunction in heart failure patients? In this engaging podcast Associate Editor Leon De Windt interviews lead author Masafumi Kitakaze (National Cerebral and Cardiovascular Center, Japan) and expert Thomas Thum (Hannover Medical School, Germany) about the pioneering work by Kitakaze and colleagues, which investigated the correlation between circulating FGF23 in non-ischemic patients with early chronic kidney disease and higher incidences of heart failure hospitalization in these patients. How did inflammation, ischemic conditions, gender, age, and other medications influence circulating FGF23 levels? Listen now.

Miki Imazu, Hiroyuki Takahama, Hiroshi Asanuma, Akira Funada, Yasuo Sugano, Takahiro Ohara, Takuya Hasegawa, Masanori Asakura, Hideaki Kanzaki, Toshihisa Anzai, Masafumi Kitakaze Pathophysiological Impact of Serum Fibroblast Growth Factor 23 in Patients with Non-ischemic Cardiac Disease and Early Chronic Kidney Disease Am J Physiol Heart Circ Physiol, published November 15, 2014. DOI: 10.1152/ajpheart.00331.2014.